FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Stem Cell Rev Rep / Characterization of the Proteins Secreted by Equine Muscle-D...
Stem cell reviews and reports2022; 19(2); 550-567; doi: 10.1007/s12015-022-10463-4

Characterization of the Proteins Secreted by Equine Muscle-Derived Mesenchymal Stem Cells Exposed to Cartilage Explants in Osteoarthritis Model.

Abstract: Osteoarthritis (OA) is a highly prevalent joint degenerative disease for which therapeutic treatments are limited or invasive. Cell therapy based on mesenchymal stem/stromal cells (MSCs) is therefore seen as a promising approach for this disease, in both human and horses. As the regenerative potential of MSCs is mainly conferred by paracrine function, the goal of this study was to characterize the secreted proteins of muscle-derived MSCs (mdMSCs) in an in vitro model of OA to evaluate the putative clinical interest of mdMSCs as cell therapy for joint diseases like osteoarthritis. An equine osteoarthritis model composed of cartilage explants exposed to pro-inflammatory cytokines was first developed. Then, the effects of mdMSC co-culture on cartilage explant were studied by measuring the glycosaminoglycan release and the NO2- production. To identify the underlying molecular actors, stable isotope-labeling by amino acids in cell culture based secreted protein analyses were conducted, in the presence of serum. The relative abundance of highly sequenced proteins was finally confirmed by western blot. Co-culture with muscle-derived MSCs decreases the cytokine-induced glycosaminoglycan release by cartilage explants, suggesting a protecting effect of mdMSCs. Among the 52 equine proteins sequenced in the co-culture conditioned medium, the abundance of decorin and matrix metalloproteinase 3 was significantly modified, as confirmed by western blot analyses. These results suggest that muscle-derived MSCs could reduce the catabolic effect of TNFα and IL-1β on cartilage explant by decreasing the secretion and activity of matrix metalloproteinase 3 and increasing the decorin secretion. mdMSCs capacity to reduce the catabolic consequences of cartilage exposure to pro-inflammatory cytokines. These effects can be explained by mdMSC-secreted bioactive such as TIMP-1 and decorin, known as an inhibitor of MMP3 and an anti-inflammatory protein, respectively.
© 2022. The Author(s).
Get Full Text
Publication Date: 2022-10-22 PubMed ID: 36271312PubMed Central: PMC9902419DOI: 10.1007/s12015-022-10463-4Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The study analyses muscle-derived mesenchymal stem cells (mdMSCs) and their potential use in treating osteoarthritis, a common joint degenerative disease. The researchers used a model of osteoarthritis and found that mdMSCs decrease the induced glycosaminoglycan release and show certain molecular activities which could support their use in cell therapy for osteoarthritis.

Osteoarthritis and the Role of Mesenchymal Stem Cells

  • The research aimed to explore the potential of mesenchymal stem cells, particularly those derived from muscle (mdMSCs), in treating osteoarthritis, a degenerative joint disease prevalent in humans and horses.
  • The authors started with the development of an equine osteoarthritis model using cartilage explants exposed to pro-inflammatory cytokines.
  • Mesenchymal stem cells are seen as a promising solution for this disease due to their regenerative potential, which is mainly achieved through their paracrine function.

Study of mdMSCs’ Effects and Underlying Molecular Actors

  • The effects of co-culturing cartilage explant with mdMSCs were studied by measuring the release of glycosaminoglycan (a compound prevalent in cartilage) and nitric oxide production.
  • Amino acids in cell culture-based secreted protein analyses were conducted to identify the underlying molecular factors contributing to these effects.
  • The co-culturing of muscle-derived MSCs led to a decrease in the cytokine-induced glycosaminoglycan release by cartilage explants, indicating a protective effect of mdMSCs.

Identification of Proteins and Therapeutic Implications

  • Among many sequenced proteins in the co-culture conditioned medium, abundances of two proteins — decorin and matrix metalloproteinase 3 — were found to significantly change. Western blot analyses confirmed this.
  • The results suggest that muscle-derived MSCs could reduce the harmful impact of TNFα and IL-1β on cartilage explant by decreasing the secretion and activity of an enzyme called matrix metalloproteinase 3 and by increasing the secretion of the protein decorin.
  • These alterations could help reduce the damaging consequences of cartilage exposure to pro-inflammatory cytokines, suggesting that the use of mdMSCs could be a viable treatment for conditions like osteoarthritis.
  • The beneficial effects can be explained by the bioactives secreted by mdMSCs, such as TIMP-1 and decorin, which act as an inhibitor of the harmful enzyme matrix metalloproteinase 3 and as an anti-inflammatory protein respectively.

Cite This Article

APA
Dechêne L, Colin M, Demazy C, Fransolet M, Niesten A, Arnould T, Serteyn D, Dieu M, Renard P. (2022). Characterization of the Proteins Secreted by Equine Muscle-Derived Mesenchymal Stem Cells Exposed to Cartilage Explants in Osteoarthritis Model. Stem Cell Rev Rep, 19(2), 550-567. https://doi.org/10.1007/s12015-022-10463-4

Publication

Stem cell reviews and reports
ISSN: 2629-3277
NlmUniqueID: 101752767
Country: United States
Language: English
Volume: 19
Issue: 2
Pages: 550-567

Researcher Affiliations

Dechêne, Lola
  • Laboratory of Biochemistry and Cell Biology (URBC), NARILIS (Namur Research Institute for Life Sciences), University of Namur (UNamur), Rue de Bruxelles 61, 5000, Namur, Belgium.
  • Department of Clinical Sciences, Anesthesiology and Equine Surgery, Faculty of Veterinary Medicine, B41, University of Liege, Sart Tilman, 4000, Liège, Belgium.
Colin, Margaux
  • Department of Pharmacotherapy and Pharmaceuticals, Faculty of Pharmacy, Université Libre de Bruxelles (ULB), 1050, Brussels, Belgium.
Demazy, Catherine
  • Laboratory of Biochemistry and Cell Biology (URBC), NARILIS (Namur Research Institute for Life Sciences), University of Namur (UNamur), Rue de Bruxelles 61, 5000, Namur, Belgium.
  • Mass Spectrometry Platform (MaSUN) - Namur Research Institute for Life Sciences (Narilis), University of Namur (UNamur), 5000, Namur, Belgium.
Fransolet, Maude
  • Laboratory of Biochemistry and Cell Biology (URBC), NARILIS (Namur Research Institute for Life Sciences), University of Namur (UNamur), Rue de Bruxelles 61, 5000, Namur, Belgium.
  • Mass Spectrometry Platform (MaSUN) - Namur Research Institute for Life Sciences (Narilis), University of Namur (UNamur), 5000, Namur, Belgium.
Niesten, Ariane
  • Centre of Oxygen, Research and Development (CORD), Institute of Chemistry B6a, University of Liege (ULiège), Sart Tilman, 4000, Liège, Belgium.
Arnould, Thierry
  • Laboratory of Biochemistry and Cell Biology (URBC), NARILIS (Namur Research Institute for Life Sciences), University of Namur (UNamur), Rue de Bruxelles 61, 5000, Namur, Belgium.
Serteyn, Didier
  • Department of Clinical Sciences, Anesthesiology and Equine Surgery, Faculty of Veterinary Medicine, B41, University of Liege, Sart Tilman, 4000, Liège, Belgium.
Dieu, Marc
  • Laboratory of Biochemistry and Cell Biology (URBC), NARILIS (Namur Research Institute for Life Sciences), University of Namur (UNamur), Rue de Bruxelles 61, 5000, Namur, Belgium.
  • Mass Spectrometry Platform (MaSUN) - Namur Research Institute for Life Sciences (Narilis), University of Namur (UNamur), 5000, Namur, Belgium.
Renard, Patricia
  • Laboratory of Biochemistry and Cell Biology (URBC), NARILIS (Namur Research Institute for Life Sciences), University of Namur (UNamur), Rue de Bruxelles 61, 5000, Namur, Belgium. patsy.renard@unamur.be.
  • Mass Spectrometry Platform (MaSUN) - Namur Research Institute for Life Sciences (Narilis), University of Namur (UNamur), 5000, Namur, Belgium. patsy.renard@unamur.be.

MeSH Terms

  • Animals
  • Cartilage / metabolism
  • Chondrocytes
  • Cytokines / metabolism
  • Decorin / metabolism
  • Decorin / pharmacology
  • Glycosaminoglycans / metabolism
  • Horses
  • Matrix Metalloproteinase 3 / metabolism
  • Matrix Metalloproteinase 3 / pharmacology
  • Mesenchymal Stem Cells
  • Muscles / metabolism
  • Osteoarthritis / therapy
  • Osteoarthritis / veterinary

Conflict of Interest Statement

DS got patent for mdMSCs (WO2015091210). DS is administrator of RevaTis company, the provider of mdMSCs. Other authors have no conflict of interest.

References

This article includes 89 references
  1. Arrigoni C, Arrigo DD, Rossella V, Candrian C, Albertini V, Moretti M. Umbilical cord MSCs and their Secretome in the therapy of arthritic diseases: A research and industrial perspective. pp 1–20.
    pmc: PMC7348802pubmed: 32481562doi: 10.3390/cells9061343google scholar: lookup
  2. Mocchi M, Dotti S, Bue M Del, Villa R, Bari E, Perteghella S. Veterinary Regenerative Medicine for Musculoskeletal Disorders: Can Mesenchymal Stem/Stromal Cells and Their Secretome Be the New Frontier?. Cells 9(6).
    pmc: PMC7349187pubmed: 32545382doi: 10.3390/cells9061453google scholar: lookup
  3. Lee Y-R, Briggs MT, Condina MR, Puddy H, Anderson PH, Hoffmann P. Mass Spectrometry Imaging as a Potential Tool to Investigate Human Osteoarthritis at the Tissue Level. International Journal of Molecular Sciences 2020 Sep 15;21(17):6414.
    pmc: PMC7503948pubmed: 32899238
  4. Thysen S, Luyten FP, Lories RJU. Targets, models and challenges in osteoarthritis research. DMM Dis Model Mech 2015;8(1):17–30.
    doi: 10.1242/dmm.016881pmc: PMC4283647pubmed: 25561745google scholar: lookup
  5. Jang S, Lee K, Ju JH. Recent Updates of Diagnosis, Pathophysiology, and Treatment on Osteoarthritis of the Knee. Molecular Sciences 2021.
    pmc: PMC7961389pubmed: 33807695doi: 10.3390/ijms22052619google scholar: lookup
  6. Harrell C, Markovic BS, Fellabaum C, Arsenijevic A, Volarevic V. Mesenchymal stem cell-based therapy of osteoarthritis: Current knowledge and future perspectives. Biomed Pharmacother 109(June 2018):2318–26.
    pubmed: 30551490doi: 10.1016/j.biopha.2018.11.099google scholar: lookup
  7. Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Experimental & Molecular Medicine 2013;45(11):e54–e54.
    pmc: PMC3849579pubmed: 24232253
  8. Naji A, Eitoku M, Favier B, Deschaseaux F, Rouas-Freiss N, Suganuma N. Biological functions of mesenchymal stem cells and clinical implications. Cellular and Molecular Life Sciences 76(17):3323–48.
    pmc: PMC11105258pubmed: 31055643doi: 10.1007/s00018-019-03125-1google scholar: lookup
  9. Samsonraj RM, Raghunath M, Nurcombe V, Hui JH, van Wijnen AJ, Cool SM. Concise Review: Multifaceted Characterization of Human Mesenchymal Stem Cells for Use in Regenerative Medicine. Stem Cells Translational Medicine 6:2173–85.
    pmc: PMC5702523pubmed: 29076267doi: 10.1002/sctm.17-0129google scholar: lookup
  10. Ceusters J, Lejeune JP, Sandersen C, Niesten A, Lagneaux L, Serteyn D. From skeletal muscle to stem cells: An innovative and minimally-invasive process for multiple species. Scientific Reports .
    pmc: PMC5429713pubmed: 28386120doi: 10.1038/s41598-017-00803-7google scholar: lookup
  11. Gunn C. Muscle, bone and fat proportions and the muscle distribution of Thoroughbreds and other horses. Equine Exerc Physiol 1987;2:253–264.
  12. Usas A, Huard J. Muscle-derived stem cells for tissue engineering and regenerative therapy. Biomaterials 28(36):5401–6.
    pmc: PMC2095130pubmed: 17915311
  13. Bundgaard L, Stensballe A, Elbæk KJ, Berg LC. Mass spectrometric analysis of the in vitro secretome from equine bone marrow-derived mesenchymal stromal cells to assess the effect of chondrogenic differentiation on response to interleukin-1β treatment. Stem Cell Research & Therapy 2020;11(1):187.
    doi: 10.1186/s13287-020-01706-7pmc: PMC7238576pubmed: 32434555google scholar: lookup
  14. Bapat S, Hubbard D, Munjal A, Hunter M, Fulzele S. Pros and cons of mouse models for studying osteoarthritis. Clinical and Translational Medicine 7(1):36.
    pmc: PMC6246759pubmed: 30460596doi: 10.1186/s40169-018-0215-4google scholar: lookup
  15. Peffers MJ, Cillero-Pastor B, Eijkel GB, Clegg PD, Heeren RM. Matrix assisted laser desorption ionization mass spectrometry imaging identifies markers of ageing and osteoarthritic cartilage. Arthritis Research & Therapy .
    pmc: PMC4095688pubmed: 24886698doi: 10.1186/ar4560google scholar: lookup
  16. Malda Benders K, Klein T, de G J C, Kik M, Hutmacher D. Comparative study of depth-dependent characteristics of equine and human osteochondral tissue from the medial and lateral femoral condyles. Osteoarthritis and Cartilage 20(10):1147–51.
    pubmed: 22781206
  17. Cope PJ, Ourradi K, Li Y, Sharif M. Models of osteoarthritis: The good, the bad and the promising. Osteoarthritis and Cartilage 2019;27(2):230–239.
    doi: 10.1016/j.joca.2018.09.016pmc: PMC6350005pubmed: 30391394google scholar: lookup
  18. McIlwraith CW, Kawcak CE, Frisbie DD, Little CB, Clegg PD, Peffers MJ. Biomarkers for equine joint injury and osteoarthritis. Journal of Orthopaedic Research 2018;36(3):823–831.
    pubmed: 28921609
  19. Bertuglia A, Pagliara E, Grego E, Ricci A, Brkljaca-Bottegaro N. Pro-inflammatory cytokines and structural biomarkers are effective to categorize osteoarthritis phenotype and progression in Standardbred racehorses over five years of racing career. BMC Veterinary Research 12(1):1–15.
    pmc: PMC5100096pubmed: 27821120doi: 10.1186/s12917-016-0873-7google scholar: lookup
  20. Strauss E, Goodrich L, Chen C-T, Hidaka C, Nixon A. Biochemical and biomechanical properties of lesion and adjacent articular cartilage after chondral defect repair in an equine model. The American Journal of Sports Medicine 33(11):1647–53.
    pubmed: 16093540
  21. McCoy AM. Animal Models of Osteoarthritis: Comparisons and Key Considerations. Veterinary Pathology 2015;52(5):803–818.
    doi: 10.1177/0300985815588611pubmed: 26063173google scholar: lookup
  22. Smith RKW. Mesenchymal stem cell therapy for equine tendinopathy. Disability and Rehabilitation 30(20–22):1752–8.
    pubmed: 18608378
  23. Marycz K, Toker NY, Grzesiak J, Wrzeszcz K, Golonka P. The therapeutic effect of autogenic adipose derived stem cells combined with autogenic platelet rich plasma in tendons disorders in horses in vitro and in vivo research. Journal of Animal and Veterinary Advances 2012;11(23):4324–4331.
  24. Voga M, Majdic G. Articular Cartilage Regeneration in Veterinary Medicine. Advances in Experimental Medicine and Biology .
    pubmed: 35733035doi: 10.1007/5584_2022_717google scholar: lookup
  25. Dias IE, Pinto PO, Barros LC, Viegas CA, Dias IR, Carvalho PP. Mesenchymal stem cells therapy in companion animals: useful for immune-mediated diseases?. BMC Veterinary Research 2019;15(1):358.
    doi: 10.1186/s12917-019-2087-2pmc: PMC6805418pubmed: 31640767google scholar: lookup
  26. Cequier A, Sanz C, Rodellar C, Barrachina L. The usefulness of mesenchymal stem cells beyond the musculoskeletal system in horses. Animals 11.
    pmc: PMC8064371pubmed: 33805967
  27. Marycz K, Weiss C, Śmieszek A, Kornicka K. Evaluation of oxidative stress and mitophagy during adipogenic differentiation of adipose-derived stem cells isolated from equine metabolic syndrome (EMS) horses. Stem Cells International .
    pmc: PMC6011082pubmed: 29977307doi: 10.1155/2018/5340756google scholar: lookup
  28. Fortier LA, Travis AJ. Stem cells in veterinary medicine. Stem Cell Research & Therapy 2(1).
    pmc: PMC3092149pubmed: 21371354
  29. Colbath AC, Dow SW, McIlwraith CW, Goodrich LR. Mesenchymal stem cells for treatment of musculoskeletal disease in horses: Relative merits of allogeneic versus autologous stem cells. Equine Veterinary Journal 2020;52(5):654–663.
    doi: 10.1111/evj.13233pubmed: 31971273google scholar: lookup
  30. Zayed M, Adair S, Ursini T, Schumacher J, Misk N, Dhar M. Concepts and challenges in the use of mesenchymal stem cells as a treatment for cartilage damage in the horse. Research in Veterinary Science 118(December 2017):317–23.
    pubmed: 29601969doi: 10.1016/j.rvsc.2018.03.011google scholar: lookup
  31. Ferreira JR, Teixeira GQ, Santos SG, Barbosa MA, Almeida-Porada G, Gonçalves RM. Mesenchymal stromal cell secretome: Influencing therapeutic potential by cellular pre-conditioning. Frontiers in Immunology 9(December):1–17.
    pmc: PMC6288292pubmed: 30564236
  32. Maffioli E, Nonnis S, Angioni R, Santagata F, Calì B, Zanotti L. Proteomic analysis of the secretome of human bone marrow-derived mesenchymal stem cells primed by pro-inflammatory cytokines. Journal of Proteomics 23(166):115–126.
    doi: 10.1016/j.jprot.2017.07.012pubmed: 28739509google scholar: lookup
  33. Shin J, Rhim J, Kwon Y, Choi SY, Shin S, Ha CW. Comparative analysis of differentially secreted proteins in serum-free and serum-containing media by using BONCAT and pulsed SILAC. Scientific Reports 9(1):1–12.
    pmc: PMC6395664pubmed: 30816242doi: 10.1038/s41598-019-39650-zgoogle scholar: lookup
  34. Kupcova Skalnikova H. Proteomic techniques for characterisation of mesenchymal stem cell secretome. Biochimie 95(12):2196–211.
    pubmed: 23880644doi: 10.1016/j.biochi.2013.07.015google scholar: lookup
  35. Ong SE, Mann M. A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nature Protocols 1(6):2650–2660.
    doi: 10.1038/nprot.2006.427pubmed: 17406521google scholar: lookup
  36. Dignam JD, Martin PL, Shastry BS, Roeder RG. Eukaryotic gene transcription with purified components. Methods in Enzymology 101(C):582–98.
    pubmed: 6888276
  37. Ong S, Blagoev B, Kratchmarova I, Kristensen D, Steen H, Pandey A. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Molecular & Cellular Proteomics 1(5):376–86.
    pubmed: 12118079
  38. Liu R, Wang Y, Li B, Wang H, Guan F, Tan Z. Screening differentially expressed proteins from co-cultured hematopoietic cells and bone marrow-derived stromal cells by quantitative proteomics (SILAC) method. Clinical Proteomics 16(1):1–18.
    pmc: PMC6637644pubmed: 31360146doi: 10.1186/s12014-019-9249-xgoogle scholar: lookup
  39. Park SS, Wu WW, Zhou Y, Shen RF, Martin B, Maudsley S. Effective correction of experimental errors in quantitative proteomics using stable isotope labeling by amino acids in cell culture (SILAC). Journal of Proteomics 75(12):3720–32.
    pmc: PMC3394155pubmed: 22575385
  40. Distler U, Kuharev J, Navarro P, Tenzer S. Label-free quantification in ion mobility–enhanced data-independent acquisition proteomics. Nature Protocols 11(4):795–812.
    pubmed: 27010757
  41. Meier F, Brunner AD, Koch S, Koch H, Lubeck M, Krause M. Online parallel accumulation–serial fragmentation (PASEF) with a novel trapped ion mobility mass spectrometer. Molecular & Cellular Proteomics 17(12):2534–45.
    pmc: PMC6283298pubmed: 30385480
  42. Weinmann D, Mueller M, Walzer SM, Hobusch GM, Lass R, Gahleitner C. Brazilin blocks catabolic processes in human osteoarthritic chondrocytes via inhibition of NFKB1/p50. Journal of Orthopaedic Research 36(9):2431–8.
    pubmed: 29704279
  43. Little CB, Flannery CR, Hughes CE, Goodship A, Caterson B. Cytokine induced metalloproteinase expression and activity does not correlate with focal susceptibility of articular cartilage to degeneration. Osteoarthritis and Cartilage 13(2):162–70.
    pubmed: 15694578
  44. Huh JE, Baek YH, Ryu SR, Lee JD, Choi DY, Park DS. Efficacy and mechanism of action of KHBJ-9B, a new herbal medicine, and its major compound triterpenoids in human cartilage culture and in a rabbit model of collagenase-induced osteoarthritis. International Immunopharmacology 9(2):230–40.
    pubmed: 19100343
  45. Matta C, Fellows CR, Quasnichka H, Williams A, Jeremiasse B, Allaway D. Clusterin secretion is attenuated by the proinflammatory cytokines interleukin-1β and tumor necrosis factor-α in models of cartilage degradation. Journal of Orthopaedic Research 39(5).
    pubmed: 32725904
  46. Clutterbuck AL, Smith JR, Allaway D, Harris P, Liddell S, Mobasheri A. High throughput proteomic analysis of the secretome in an explant model of articular cartilage inflammation. Journal of Proteomics 74(5):704–15.
    pmc: PMC3078332pubmed: 21354348
  47. Haseeb A, Haqqi TM. Immunopathogenesis of osteoarthritis. Clinical Immunology 146:185–96.
    pmc: PMC4015466pubmed: 23360836
  48. PA B, M L, JW P, D B. Phorbol-ester-induced activation of the NF-kappa B transcription factor involves dissociation of an apparently cytoplasmic NF-kappa B/inhibitor complex. Cold Spring Harbor Symposia on Quantitative Biology 53 Pt 2(2):789–98.
    pubmed: 3076097
  49. Cook AE, Cook JL, Stoker AM. Metabolic Responses of Meniscus to IL-1β. Journal of Knee Surgery 31(9):834–40.
    pubmed: 29294496
  50. Madzuki IN, Lau SF, Che Ahmad Tantowi NA, Mohd Ishak NI, Mohamed S. Labisia pumila prevented osteoarthritis cartilage degeneration by attenuating joint inflammation and collagen breakdown in postmenopausal rat model. Inflammopharmacology 26(5):1207–17.
    pubmed: 29460078
  51. Kardos D, Marschall B, Simon M, Hornyák I, Hinsenkamp A, Kuten O. Investigation of Cytokine Changes in Osteoarthritic Knee Joint Tissues in Response to Hyperacute Serum Treatment. Cells 8(8).
    pmc: PMC6721638pubmed: 31382623doi: 10.3390/cells8080824google scholar: lookup
  52. Anderson JR, Phelan MM, Foddy L, Clegg PD, Peffers MJ. Ex Vivo Equine Cartilage Explant Osteoarthritis Model: A Metabolomics and Proteomics Study. Journal of Proteome Research 19(9):3652–67.
    pmc: PMC7476031pubmed: 32701294
  53. Chen S, Fu P, Wu H, Pei M. Meniscus, articular cartilage and nucleus pulposus: a comparative review of cartilage-like tissues in anatomy, development and function. Cell and Tissue Research 370:53–70.
    pmc: PMC5645221pubmed: 28413859
  54. Krishnan Y, Grodzinsky AJ. Cartilage diseases. Matrix Biology .
    pmc: PMC6146013pubmed: 29803938doi: 10.1016/j.matbio.2018.05.005google scholar: lookup
  55. Kwon JH, Kim M, Bae YK, Kim G-H, Choi SJ, Oh W. Decorin Secreted by Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Induces Macrophage Polarization via CD44 to Repair Hyperoxic Lung Injury. International Journal of Molecular Sciences 20.
    pmc: PMC6801980pubmed: 31569732doi: 10.3390/ijms20194815google scholar: lookup
  56. Araki Y, Mimura T. Matrix metalloproteinase gene activation resulting from disordred epigenetic mechanisms in rheumatoid arthritis. International Journal of Molecular Sciences .
    pmc: PMC5454818pubmed: 28441353doi: 10.3390/ijms18050905google scholar: lookup
  57. Lin Z, Li Z, Li EN, Li X, Del Duke CJ, Shen H. Osteochondral Tissue Chip Derived From iPSCs: Modeling OA Pathologies and Testing Drugs. Frontiers in Bioengineering and Biotechnology 7.
    pmc: PMC6930794pubmed: 31921815doi: 10.3389/fbioe.2019.00411google scholar: lookup
  58. Abbott J, Holtzer H. The loss of phenotypic traits by differentiated cells. The reversible behavior of chondrocytes in primary cultures. The Journal of Cell Biology 28(3):473–487.
    doi: 10.1083/JCB.28.3.473pmc: PMC2106945pubmed: 4163861google scholar: lookup
  59. Hall AC. The Role of Chondrocyte Morphology and Volume in Controlling Phenotype—Implications for Osteoarthritis, Cartilage Repair, and Cartilage Engineering. Current Rheumatology Reports 21.
    pmc: PMC6571082pubmed: 31203465
  60. Strehl R, Tallheden T, Sjögren-Jansson E, Minuth WW, Lindahl A. Long-term maintenance of human articular cartilage in culture for biomaterial testing. Biomaterials 26(22):4540–9.
    pubmed: 15722123
  61. Moo EK, Osman NAA, Pingguan-Murphy B. The metabolic dynamics of cartilage explants over a long-term culture period. Clinics 66(8):1431–6.
    pmc: PMC3161224pubmed: 21915496
  62. Gilbert SJ, Singhrao SK, Khan IM, Gonzalez LG, Thomson BM, Burdon D. Enhanced tissue integration during cartilage repair in vitro can be achieved by inhibiting chondrocyte death at the wound edge. Tissue Engineering - Part A 15(7):1739–49.
    pubmed: 19119922
  63. Li L, Li Z, Li Y, Hu X, Zhang Y, Fan P. Profiling of inflammatory mediators in the synovial fluid related to pain in knee osteoarthritis. BMC Musculoskeletal Disorders 21(1):99.
    doi: 10.1186/s12891-020-3120-0pmc: PMC7023718pubmed: 32059658google scholar: lookup
  64. Li K, Zhang P, Zhu Y, Alini M, Grad S, Li Z. Establishment of an Ex Vivo Inflammatory Osteoarthritis Model With Human Osteochondral Explants. Frontiers in Bioengineering and Biotechnology 9.
    pmc: PMC8724558pubmed: 34993189
  65. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Molecular and Cellular Biochemistry 10(5):2327–34.
    pmc: PMC360580pubmed: 2183031
  66. Borghaei RC, Rawlings PL, Javadi M, Woloshin J. NF-κB binds to a polymorphic repressor element in the MMP-3 promoter. Biochemical and Biophysical Research Communications 316(1):182–8.
    pubmed: 15003528
  67. Morris KR, Lutz RD, Choi HS, Kamitani T, Chmura K, Chan ED. Role of the NF-kappaB signaling pathway and kappaB cis-regulatory elements on the IRF-1 and iNOS promoter regions in mycobacterial lipoarabinomannan induction of nitric oxide. Infection and Immunity 71(3):1442–52.
    pmc: PMC148845pubmed: 12595462
  68. Porée B, Kypriotou M, Chadjichristos C, Beauchef G, Renard E, Legendre F. Interleukin-6 (IL-6) and/or soluble IL-6 receptor down-regulation of human type II collagen gene expression in articular chondrocytes requires a decrease of Sp1.Sp3 ratio and of the binding activity of both factors to the COL2A1 promoter. The Journal of Biological Chemistry 283(8):4850–65.
    pubmed: 18065760
  69. Sui Y, Lee JH, DiMicco MA, Vanderploeg EJ, Blake SM, Hung HH. Mechanical injury potentiates proteoglycan catabolism induced by interleukin-6 with soluble interleukin-6 receptor and tumor necrosis factor alpha in immature bovine and adult human articular cartilage. Arthritis and Rheumatism 60(10):2985–96.
    pubmed: 19790045
  70. Wiegertjes R, Van De Loo FAJ, Blaney Davidson EN. A roadmap to target interleukin-6 in osteoarthritis. Rheumatology (Oxford) 59(10):2681–94.
    pmc: PMC7516110pubmed: 32691066
  71. Lotz M, Guerne PA. Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating activity (TIMP-1/EPA). The Journal of Biological Chemistry 266(4):2017–20.
    pubmed: 1846608
  72. Pelletier JP, Lascau-Coman V, Jovanovic D, Fernandes JC, Manning P, Connor JR. Selective inhibition of inducible nitric oxide synthase in experimental osteoarthritis is associated with reduction in tissue levels of catabolic factors. The Journal of Rheumatology 26(9):2002–14.
    pubmed: 10493683
  73. Abramson SB. Osteoarthritis and nitric oxide. Osteoarthritis and Cartilage 16 Suppl 2.
    pubmed: 18794013
  74. Faienza F, Rasola A, Filomeni G. Nitric oxide-based regulation of metabolism: Hints from TRAP1 and SIRT3 crosstalk. Frontiers in Molecular Biosciences 9.
    pmc: PMC9360569pubmed: 35959462doi: 10.3389/fmolb.2022.942729google scholar: lookup
  75. Sasaki K, Hattori T, Fujisawa T, Takahashi K, Inoue H, Takigawa M. Nitric oxide mediates interleukin-1-induced gene expression of matrix metalloproteinases and basic fibroblast growth factor in cultured rabbit articular chondrocytes. Journal of Biochemistry 123(3):431–9.
    pubmed: 9538225
  76. Xian Bo S, Yan Jie W, De Chao C, Sai M, Zhe W, Ya Kun Z. An inducible nitric oxide synthase dimerization inhibitor prevents the progression of osteoarthritis. Frontiers in Pharmacology 13.
    pmc: PMC9334866pubmed: 35910349doi: 10.3389/fphar.2022.861183google scholar: lookup
  77. Ruiz M, Toupet K, Maumus M, Rozier P, Jorgensen C, Noël D. TGFBI secreted by mesenchymal stromal cells ameliorates osteoarthritis and is detected in extracellular vesicles. Biomaterials 1(226):119544.
    doi: 10.1016/j.biomaterials.2019.119544pubmed: 31648137google scholar: lookup
  78. Simental-Mendía M, Lozano-Sepúlveda SA, Pérez-Silos V, Fuentes-Mera L, Martínez-Rodríguez HG, Acosta-Olivo CA. Anti-inflammatory and anti-catabolic effect of non-animal stabilized hyaluronic acid and mesenchymal stem cell-conditioned medium in an osteoarthritis coculture model. Molecular Medicine Reports 21(5):2243–50.
    pubmed: 32323772
  79. Wilson A, Hodgson-Garms M, Frith JE, Genever P. Multiplicity of mesenchymal stromal cells: Finding the right route to therapy. Frontiers in Immunology .
    pmc: PMC6535495pubmed: 31164890doi: 10.3389/fimmu.2019.01112google scholar: lookup
  80. Mianehsaz E, Mirzaei HR, Mahjoubin-Tehran M, Rezaee A, Sahebnasagh R, Pourhanifeh MH. Mesenchymal stem cell-derived exosomes: A new therapeutic approach to osteoarthritis?. Stem Cell Research and Therapy 10.
    pmc: PMC6873475pubmed: 31753036
  81. Sanchez C, Bay-Jensen AC, Pap T, Dvir-Ginzberg M, Quasnichka H, Barrett-Jolley R. Chondrocyte secretome: a source of novel insights and exploratory biomarkers of osteoarthritis. Osteoarthritis and Cartilage .
    pubmed: 28232143doi: 10.1016/j.joca.2017.02.797google scholar: lookup
  82. Grafe I, Alexander S, Peterson JR, Snider TN, Levi B, Lee B, Mishina Y. TGF-β family signaling in Mesenchymal differentiation. Cold Spring Harbor Perspectives in Biology 10(5):a022202.
    pmc: PMC5932590pubmed: 28507020doi: 10.1101/cshperspect.a022202google scholar: lookup
  83. de Araújo Farias V, Carrillo-Gálvez AB, Martín F, Anderson P. TGF-β and mesenchymal stromal cells in regenerative medicine, autoimmunity and cancer. Cytokine Growth Factor Rev 43:25–37.
    pubmed: 29954665doi: 10.1016/j.cytogfr.2018.06.002google scholar: lookup
  84. Mehana ESE, Khafaga AF, El-Blehi SS. The role of matrix metalloproteinases in osteoarthritis pathogenesis: An updated review. Life Sciences .
    pubmed: 31445934doi: 10.1016/j.lfs.2019.116786google scholar: lookup
  85. Blom AB, Van Lent PL, Libregts S, Holthuysen AE, Van Der Kraan PM, Van Rooijen N. Crucial role of macrophages in matrix metalloproteinase-mediated cartilage destruction during experimental osteoarthritis: involvement of matrix metalloproteinase 3. Arthritis and Rheumatism 56(1):147–57.
    pubmed: 17195217
  86. Gardner J, Ghorpade A. Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous system. Journal of Neuroscience Research 74(6):801–6.
    pmc: PMC3857704pubmed: 14648584
  87. Singla S, Hu C, Mizeracki A, Mehta JL. Decorin in atherosclerosis. Therapeutic Advances in Cardiovascular Disease 5(6):305–14.
    pubmed: 22089475
  88. Guarise C, Ceradini D, Tessari M, Pavan M, Moro S, Salmaso V. Amphiphilic peptide-based MMP3 inhibitors for intra-articular treatment of knee OA. Bioorganic & Medicinal Chemistry 15(38):116132.
    doi: 10.1016/j.bmc.2021.116132pubmed: 33872958google scholar: lookup
  89. Perez-Riverol Y, Bai J, Bandla C, García-Seisdedos D, Hewapathirana S, Kamatchinathan S. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Research 50(D1):D543–52.
    pmc: PMC8728295pubmed: 34723319
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.